NVO
Novo Nordisk A/S
NVO has the edge over STOK overall, supported by stronger fundamentals and stronger modeled upside.
STOK
Stoke Therapeutics, Inc.
STOK has slightly lower modeled downside risk, despite its lower overall score.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STOK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
STOK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STOK PE Valuation
STOK has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STOK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STOK's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over STOK on earnings quality, reporting a profit while its opponent remains loss making.
STOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.77 | -639% |
| Q2 2026 | -$3.34 | -480% |
| Q1 2026 | -$2.81 | -443% |
| Q4 2025 | -$0.12 | +$1.53 |
| Q3 2025 | $0.70 | +$2.81 |
| Q2 2025 | $0.88 | +$3.07 |
| Q1 2025 | $0.82 | +$3.24 |
| Q4 2024 | -$1.65 | +$0.73 |
STOK has swung to a loss: it lost $3.77 per share over the past year, after a profit the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STOK on profitability, with a higher operating margin.
STOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | +5.9% |
| Q2 2026 | $9.3M | -33% |
| Q1 2026 | $6.2M | -96% |
| Q4 2025 | $1.4M | -94% |
| Q3 2025 | $10.6M | +117% |
| Q2 2025 | $13.8M | +186% |
| Q1 2025 | $158.6M | +3661% |
| Q4 2024 | $22.6M | +707% |
STOK's revenue is recovering but still below its 2025 peak: $11M last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -687% | -282 points |
| Q2 2026 | -702% | -504 points |
| Q1 2026 | -858% | -928 points |
| Q4 2025 | -4382% | -4322 points |
| Q3 2025 | -405% | +208 points |
| Q2 2025 | -198% | +410 points |
| Q1 2025 | 70% | +743 points |
| Q4 2024 | -60% | +996 points |
STOK's operating margin was −687% last quarter, down 282 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over STOK on cash generation, producing positive trailing cash flow while its opponent burns cash.
STOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$65.5M | -$35M |
| Q2 2026 | -$58.6M | -$33M |
| Q1 2026 | -$60.9M | -146% |
| Q4 2025 | -$30.7M | -$7.5M |
| Q3 2025 | -$30.5M | -$8.8M |
| Q2 2025 | -$25.6M | -$8.1M |
| Q1 2025 | $131.7M | +$156.3M |
| Q4 2024 | -$23.2M | -$2.4M |
STOK has burned cash in almost every quarter: −$216M over the past year, against $52M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STOK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +2.3M shares |
| 1 year | +17% | +9.8M shares |
| 3 years | +54% | +24.1M shares |
| 5 years | +86% | +31.6M shares |
| Available history | +108% | +35.5M shares |
STOK has 68M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.9x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.8x | Net Cash |
STOK has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 36.1 | Neutral |
STOK's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STOK PE vs Healthcare Sector
| Metric | STOK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STOK has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
STOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.4 | 3.1% above |
| 20 week MA | $28.5 | 8% below |
| 50 week MA | $30.7 | 15% below |
| 100 week MA | $22.9 | 14% above |
| 200 week MA | $16.2 | 61% above |
STOK has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.6 | $58.3 | +119% |
| 2021 | $58.3 | $21.6 | -63% |
| 2022 | $21.6 | $8.30 | -62% |
| 2023 | $8.30 | $5.26 | -37% |
| 2024 | $5.26 | $11.1 | +110% |
| 2025 | $11.1 | $31.9 | +189% |
| 2026 YTD | $31.9 | $26.2 | -18% |
STOK has the edge over NVO on returns for 2026, with the stronger performance.